Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04795752
Other study ID # 07093
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 23, 2021
Est. completion date May 22, 2024

Study information

Verified date September 2022
Source Sight Sciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 350
Est. completion date May 22, 2024
Est. primary completion date March 22, 2024
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - At least 22 years of age - Reports dry eye symptoms within the past 3 to 6 months - Reports having to use artificial tears or lubricants regularly over the past month to relieve dry eye symptoms. - Schirmer tear test (with anesthesia) =1 to =10 mm in 5 minutes - OSDI Score of 23-79 - TBUT of =1 to =7 seconds in both eyes - Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score =12 in each eye. - At least 15 glands in each lower eyelid should be expressible, with a sterile cotton swab, at the slit lamp. - Best corrected visual acuity of 20/100 or better in both eyes. - Willing and able to comply with the study procedures and follow-up - Willing and able to provide informed consent - English-speaking Exclusion Criteria: - Use of any of the following medications: 1. Cyclosporine (Restasis, Cequa etc.) or Xiidra within 60 days prior to enrollment; 2. Antihistamines (oral or topical) within 10 days prior to enrollment; 3. Systemic medication(s) (other than antihistamines) that is known to cause ocular dryness (e.g. diuretics, anti-hypertensives, anti-depressants, hormone therapy) and whose dose of this medication(s) has not been stable within 30 days prior to enrollment. There must be no anticipated adjustments to the dose of these medications for the duration of the trial; 4. Accutane (at any time); 5. Oral tetracyclines or azithromycin within 30 days prior to enrollment; or 6. Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, non-steroidal anti- inflammatory medications within 30 days prior to enrollment. - Any of the following dry eye treatments: 1. Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [Lipiflow], iLux etc.) within 12 months prior to enrollment either as part of routine care or clinical investigation; 2. Meibomian gland expression within 6 months prior to enrollment; 3. Blephex or debridement within 3 months prior to enrollment is an exclusion; 4. Punctal occlusion or punctal plugs. Investigators can choose to remove the punctal plugs 15 days prior to enrollment; 5. Use of TrueTear device within the past 2 weeks. (Subjects must refrain from using the TrueTear device for the duration of the study.); or 6. Any history of meibomian gland probing - History of eyelid, conjunctiva or corneal surgery (including refractive surgery) within the past year. In addition, subjects with any history of the following are excluded: chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery. - Contact lens use within the past 2 weeks. - History of Ocular Herpes Simplex or Ocular Herpes Zoster - Any active, clinically significant ocular or peri-ocular infection or inflammation - Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to enrollment - Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded. - Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis). - Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area.

Study Design


Intervention

Device:
TearCare System
TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
Drug:
Restasis
Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.

Locations

Country Name City State
United States Vantage Eye Care Bala-Cynwyd Pennsylvania
United States Vision Institute Colorado Springs Colorado
United States Cincinnati Eye Institute Edgewood Kentucky
United States Scripps Health La Jolla California
United States Harvard Eye Associates Laguna Hills California
United States Jackson Eye Lake Villa Illinois
United States Kentucky Eye Institute Lexington Kentucky
United States Loh Ophthalmology Associates Miami Florida
United States Eye Research Foundation Newport Beach California
United States University of Pittsburg-Ophthalmology Dept Pittsburgh Pennsylvania
United States Parkhurst NuVision San Antonio Texas
United States Doctor My Eyes Scottsdale Arizona
United States Vita Eye Clinic Shelby North Carolina
United States Vance Thompson Vision Sioux Falls South Dakota

Sponsors (1)

Lead Sponsor Collaborator
Sight Sciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tear Break-Up Time Mean Change from baseline in Tear Break-Up Time (TBUT) 6 months
Primary OSDI Score Mean Change from baseline in OSDI score 6 months
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A